Filing Details
- Accession Number:
- 0001225208-10-015532
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-06-21 13:00:00
- Reporting Period:
- 2010-06-17
- Filing Date:
- 2010-06-21
- Accepted Time:
- 2010-06-21 16:01:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 885725 | Boston Scientific Corp | BSX | Surgical & Medical Instruments & Apparatus (3841) | 042695240 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 901458 | M Peter Nicholas | One Boston Scientific Place Natick MA 01760-1537 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-06-17 | 25,000 | $6.03 | 8,431,021 | No | 4 | S | Indirect | By Ltd. Partnership |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | By Ltd. Partnership |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Forward Sale Contract (obligation to sell) | Acquisiton | 2010-06-17 | 237,240 | $0.00 | 237,240 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 237,240 | 2012-06-18 | 2012-06-18 | No | 4 | J | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 9,212,125 | Direct | |
| Common Stock | 2,413,088 | Indirect | By Trust 2 |
Footnotes
- Sales reported on this form were transacted pursuant to a 10b5-1 trading plan.
- The weighted average sales price is reported as stock sales were aggregated for reporting purposes. The per share transaction price ranged from $6.16 to $6.06. The reporting person will provide, upon request from an appropriate party, the per share sales volumes and prices.
- Shares held by a trust of which the reporting person's spouse and brother are trustees and the reporting person's spouse and children are beneficiaries.
- On March 1, 2010, the reporting person entered into a Rule 10b5-1 trading plan with an unaffiliated commercial bank to execute a series of variable prepaid forward sale contracts. Under the contract reported on this form, the reporting person will deliver to the bank up to 237,240 shares of the Issuer's common stock depending on market prices at maturity on June 18, 2012. If the market price per share at maturity is equal to or less than the floor price of $6.0123 per share, the reporting person will deliver 237,240 shares to the bank. If the market price per share at maturity is greater than the floor price, the reporting person will deliver a fewer number of shares. In exchange, the bank is obligated to pay $1,007,008.78 to the reporting person two business days after the date of the contract. At the option of the reporting person, the contract may be settled at maturity by delivering cash in lieu of stock.
- The reporting person pledged 237,240 shares of the Issuer's common stock to secure its obligations under the contract and retains dividends and voting rights in the shares during the term of the pledge.
Billionaire Hedge Funds
